期刊文献+

黄斑格栅样激光光凝联合玻璃体腔注射曲安奈德治疗糖尿病性黄斑水肿的疗效分析 被引量:8

Therapeutic effect of macular laser grid photocoagulation and intravitreal triamcinolone acetonide on diabetic macular edema
下载PDF
导出
摘要 目的评价黄斑格栅样激光光凝联合玻璃体腔注射曲安奈德(IVTA)对糖尿病性黄斑水肿(DME)的治疗效果。方法将DME患者48例(60眼)分成A、B、C组,每组20眼,A组行单纯黄斑区格栅样激光光凝治疗,B组行单纯IVTA治疗,C组在IVTA 4 mg后2周行黄斑区格栅样激光光凝。观察3组治疗前及治疗后1、3、6个月的视力,黄斑中心凹厚度。结果 3组患者治疗前视力、黄斑中心凹厚度差异均无统计学意义(P>0.05),3组治疗后1、3、6个月,视力、黄斑中心凹厚度比较:A组与B组差异无统计学意义(P>0.05),A、B组分别与C组比较差异有统计学意义(P<0.05)。结论黄斑格栅样激光光凝联合IVTA优于单纯激光及单纯玻璃体腔注药。(中国眼耳鼻喉科杂志,2014,14:92-95) Objective To evaluate the clinical outcome of macular laser grid photocoagulation (MLGP) combined intravitreal triamc acetonide(IVTA)for diabetic macular edema (DME). Methods Sixty eyes of 48 patients with diabetic macular edema were randomly divided into three groups:the A group was treated with simple macular laser grid photocoagulation (n = 20) ;the B group was treated with intravitreal triamcinoloue acetonide (IVTA) (n = 20) ;the C group was treated with macular laser grid photocoagulation 2 weeks after 4 mg IVTA. Then the visual acuity and macular thickness of the eyes in three groups were observed 1,3 and 6 months after treatment. Results The visual acuity, macular thickness of the eyes in three groups before treatment showed no significant difference ( P 〉 0.05 ). The visual acuity, macular thickness of the eyes in group A, B were better after treatment, however there was no statistically significant difference(P 〉 0.05 ). The visual acuity and macular thickness of the eyes in group C were better than those of group A and B with significant differences ( P 〈 0. 05 ). Conclusions IVTA combined with macular laser grid photocoagulation is superior to simple laser photocoagulation and IVTA. (Chin J Ophthalmol and Otorhinolaryngo1,2014, 14:92-95 )
出处 《中国眼耳鼻喉科杂志》 2014年第2期92-95,共4页 Chinese Journal of Ophthalmology and Otorhinolaryngology
关键词 格栅样激光光凝 黄斑水肿 糖尿病 曲安奈德 糖尿病性视网膜病变 Macular laser grid photocoaguiation Macu[ar edema Diabetes mellitus Triamc acetonide Diabetic retinopathy
  • 相关文献

参考文献10

  • 1Bhagat N, Grigorian RA, Tutela A, et al. Diabetic maeular edema: pathogenesis and treatment [ J 1. Surv Ophthalmol, 2009,54 ( 2 ) : 1-32.
  • 2Mitchell P, Bandello F, Schmidt-Effurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic maeular edema [ J 1. Ophthalmology,2011, 118(5) :615-625.
  • 3Ehrlich R, Harris A, Ciulla TA, et al. Diabetic maeular edema: physical, physiological and molecular factors contribute to this pathological process[J3. Acta Ophthalmol,2010,88(ll) :279-291.
  • 4Scholl S, Kirchhof J, Augustin AJ. Pathophysiology of maeular edema[ J]. Ophthalmologica,2010,224( S1 ) :8-15.
  • 5Hammes HP, Lin J, Renner O, et al. Perieytes and the pathogenesisof diabetic retinopathy[ J]. Diabetes,2002,5l (4) :3107-3112.
  • 6Ip MS, Bressler SB, Antoszyk AN, et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: Baseline features[ J :. Retina, 2008,28 (3) :919-930.
  • 7Martidis A,Duker JS,Greenberg PB,et al. lntravitreal triameinolone for refractory diabetic macular edema [ J ]. Ophthalmology, 2002,109 ( 3 ) :920-927.
  • 8Hailer JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema [ J 1. Arch Ophthalmol, 2010,128(5) :289-96.
  • 9Boyer DS, Faber D, Gupta S, et al. Dexamcthasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients[J]. Retina, 2011,31 (8) :915-923.
  • 10Ferrara N, Damico L, Shams N, et al. Development of ranibizumab : An anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration [ J l- Retina,2006,26 ( 7 ) : 859-870.

同被引文献69

  • 1Early TDRS.Photocoagulation for diabetic macular edema.Early treatment diabeticretinopathystudyreportnumberl [J].Arch Oph- thalmol, 1985,103(12) : 1796-1806.
  • 2Chen Z,Zhang SS,Zhu HM.Analysis of international chnical dia- betic retinopathy disease severity scale[J]. Int J Ophthalmol, 2010, 11 (8): 1394-1401.
  • 3Early Treatment, Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema.ETDRS report num- ber 1 [ J ]. Arch Ophthalmol, 1985,103 : 1796-1806.
  • 4Jonas JB, Intraocular availability of triamcinolone acetonide after intravitreal injectionEJ].Am J Ophthalmol,2004,137(5):560-562.
  • 5Roth DB,Chieh J,Spim MJ,et al.Noninfectious endophthal is as- sociated with Intravitreal triamcinolone injection [J].Arch Oph- thalmol, 2003,121 (9) : 1279.
  • 6Nguyen QD,Brown DM,Marcus DM,et al.Ranibizumab for dia- betic macular edema: Results from 2 phase III randomized trials: RISE and RIDE[J]. Ophthalmology,2012,119:789-801.
  • 7Wingate ILl, Beaumont PE.Intravitreal triamcinolone and elevat- ed intraocular pressure [J].AustNZ J Ophthalmol, 1999,27(6): 431-432.
  • 8Jonas JB, Kreissig I, Degenring R. Intraocular pressure after in- travitreal injection of triamcinolone acetonide[J].Br J Ophthal- mol, 2003,87 ( 1 ) : 24-27.
  • 9Jonas JB, Kreissig I, Degenring RF.Secondary chronic openangle glaucoma after intravitreal triamcinolne acetonide[J].Arch Oph- thalmol, 2003,121 ( 11 ) :729-730.
  • 10Bringmann A, Rerchenbach A, Wiedemann P. Pathomechanisms of cysoid macular edema. Ophthalmic Res, 2004, 36(5): 241-249.

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部